S3 Episode 4: The Future of Antibody-Drug Conjugates in Lung Cancer Treatment

Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.
Relevant disclosures can be found with the episode show notes on Medscape www.medscape.com/viewarticle/.... The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress pubmed.ncbi.nlm.nih.gov/37163...
TROP-2 Directed Antibody-Drug Conjugates (ADCs): The Revolution of Smart Drug Delivery in Advanced Non-Small Cell Lung Cancer (NSCLC) pubmed.ncbi.nlm.nih.gov/37230...
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan pubmed.ncbi.nlm.nih.gov/28548...
Gilead Provides Update on Phase 3 EVOKE-01 Study www.gilead.com/news-and-press...
EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan (SG) Plus Pembrolizumab (Pembro) With or Without Platinum Chemotherapy in First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) ascopubs.org/doi/abs/10.1200/...
Datopotamab Deruxtecan Met the PFS Endpoint in Previously Treated NSCLC dailyreporter.esmo.org/esmo-c...
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells pubmed.ncbi.nlm.nih.gov/34413...
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial pubmed.ncbi.nlm.nih.gov/37694...
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer pubmed.ncbi.nlm.nih.gov/36288...
Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint www.globenewswire.com/news-re...
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm? pubmed.ncbi.nlm.nih.gov/37370...
BL-B01D1, a First-in-Class EGFRxHER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-Human Phase 1 Study meetings.asco.org/abstracts-p...